Market capitalization | $2.60b |
Enterprise Value | $5.22b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 51.56 |
EV/Sales (TTM) EV/Sales | 1.95 |
P/S ratio (TTM) P/S ratio | 0.97 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 12.32% |
Revenue (TTM) Revenue | $2.68b |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
4 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:
4 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2,680 2,680 |
12%
12%
|
|
Gross Profit | 983 983 |
16%
16%
|
|
EBITDA | 571 571 |
13%
13%
|
EBIT (Operating Income) EBIT | 344 344 |
27%
27%
|
Net Profit | -184 -184 |
1,887%
1,887%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.
Head office | United States |
CEO | Chintu Patel |
Employees | 7,850 |
Founded | 2002 |
Website | www.amneal.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.